Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Jason Coloma Sells 34,501 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 34,501 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $27.02, for a total value of $932,217.02. Following the completion of the transaction, the chief executive officer directly owned 15,558 shares in the company, valued at approximately $420,377.16. This represents a 68.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Price Performance

MAZE stock traded down $0.22 during mid-day trading on Friday, hitting $26.43. 633,043 shares of the stock were exchanged, compared to its average volume of 665,641. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The business has a fifty day moving average price of $27.00 and a 200 day moving average price of $28.23. Maze Therapeutics, Inc. has a 12 month low of $21.95 and a 12 month high of $53.65. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -10.49 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). On average, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics in the 2nd quarter worth approximately $48,000. Royal Bank of Canada increased its stake in shares of Maze Therapeutics by 214.1% during the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after buying an additional 1,383 shares during the period. Quantbot Technologies LP purchased a new position in shares of Maze Therapeutics during the second quarter valued at approximately $80,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Maze Therapeutics during the fourth quarter valued at approximately $145,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Maze Therapeutics during the second quarter valued at approximately $200,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday, September 21st. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Maze Therapeutics in a report on Thursday, September 24th. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $63.40.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.